Literature DB >> 3900778

Recovery of renal function in patients with accelerated malignant nephrosclerosis on maintenance dialysis with management of blood pressure by captopril.

G Mourad, A Mimran, C M Mion.   

Abstract

Recovery of renal function to a self-sustaining level was observed in 4 patients with accelerated malignant hypertension who required chronic hemodialysis therapy. Excellent blood pressure control was achieved in all the patients on captopril therapy. Hemodialysis could be discontinued after 2-9 months of captopril therapy; on recovery of renal function levels of creatinine clearance became stable ranging from 28 to 56 ml/min within 5-15 months of captopril treatment, and remained at this level during 21-64 months of observation. The management of hypertension and the inhibition of the renin-angiotensin system afforded by chronic angiotensin-converting enzyme inhibition is very promising as a means of reversing the process of malignant nephrosclerosis.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3900778     DOI: 10.1159/000183574

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  3 in total

Review 1.  Systemic and regional haemodynamic profile of diuretics and alpha- and beta-blockers. A review comparing acute and chronic effects.

Authors:  A Mimran; G Ducailar
Journal:  Drugs       Date:  1988       Impact factor: 9.546

2.  Long-term renal outcome in patients with malignant hypertension: a retrospective cohort study.

Authors:  Fouad Amraoui; Sarah Bos; Liffert Vogt; Bert-Jan van den Born
Journal:  BMC Nephrol       Date:  2012-07-30       Impact factor: 2.388

3.  Malignant hypertension with protracted but not definitive oligoanuric acute kidney failure.

Authors:  Manjusha Yadla; Parvithina Sriramnaveen; Vishnubhotla Sivakumar; Chennu Krishna Kishore; Yanala Sandeep Reddy; Annapindi Venkata Sathya Sai Nagasridhar; Bobbidi Venkata Phanindra; W Herrington
Journal:  Clin Kidney J       Date:  2013-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.